A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems

NCT ID: NCT05731908

Last Updated: 2024-09-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 28 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-02-21
• Study Completion Date: 2023-04-13

Brief Summary

The main objective of this trial is to assess the effect of mild and moderate hepatic impairment (Child-Pugh classification A and B) on the pharmacokinetics, safety, and tolerability of BI 690517 in comparison with a control group with normal hepatic function.

Conditions

Liver Diseases; Healthy

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BI 690517 mild hepatic impairment (Child-Pugh A)

Group Type: EXPERIMENTAL

BI 690517

Intervention Type: DRUG

BI 690517

BI 690517 normal hepatic function

control group

Group Type: EXPERIMENTAL

BI 690517

Intervention Type: DRUG

BI 690517

BI 690517 moderate hepatic impairment (Child-Pugh B)

Group Type: EXPERIMENTAL

BI 690517

Intervention Type: DRUG

BI 690517

Interventions

BI 690517

BI 690517

Intervention Type: DRUG

Other Intervention Names

Vicadrostat

Eligibility Criteria

Inclusion Criteria

• Male or female subjects aged at least 18 years at screening
• Body mass index of 18.5 to 36.0 kg/m2 (inclusive)
• Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
• Women of childbearing potential1 and men able to father a child must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly.

• Hepatic impairment classified as Child-Pugh A (score 5-6 points) or Child-Pugh B (score 7-9 points)
• Absence of clinically significant abnormalities, as based on a complete medical history including a full physical examination, vital signs (Blood pressure, Pulse rate), 12-lead Electric Cardiogram, and clinical laboratory tests at both screening and admission to trial site, with the exception of findings that in the opinion of the investigator are consistent with the participant's hepatic impairment.
• Medication and/or treatment regimens must have been stable (i.e., no dose adjustments) for at least 4 weeks prior to the screening period and should be kept stable until study completion. Fluctuating treatment regimens may be considered for inclusion on a case-by-case basis if the underlying disease is under control in the opinion of the investigator and must be agreed to by both the investigator and the sponsor's medical monitor.

• Healthy subjects according to the following criteria: the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests.
• Individually matched to participants with hepatic impairment according to sex, age, and weight

Exclusion Criteria

• Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator
• Repeated measurements of blood pressure and pulse rate out of range considered clinically significant by the investigator
• Any laboratory value outside the reference range that the investigator considers to be of clinical relevance, except for laboratory values outside the reference range due to underlying disease
• Any evidence of a concomitant disease assessed as clinically relevant by the investigator
• Surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except cholecystectomy, appendectomy or simple hernia repair)
• Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
• History of relevant orthostatic hypotension, fainting spells, or blackouts
• Relevant chronic or acute infections

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

IQVIA global CRO

UNKNOWN

Sponsor Role: collaborator

Boehringer Ingelheim

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Omega Research Orlando, LLC

Orlando, Florida, United States

Orlando Clinical Research Center

Orlando, Florida, United States

Countries

United States

Related Links

http://www.mystudywindow.com

Related Info

Other Identifiers

1378-0016

Identifier Type: -

Identifier Source: org_study_id